Clinical trials · Washington, D.C., DC
Leukemia clinical trials in Washington, D.C.
We’re tracking 106 recruiting leukemia studies with a site in or near Washington, D.C. — including Phase 1, Phase 1/Phase 2, Phase 2 and Phase 3 studies, each written for real people, not researchers.
Recruiting studies near Washington, D.C.
- NCT05183035RecruitingPhase 3
Testing venetoclax for children with relapsed AML
This study tests a drug called venetoclax in children and young adults whose acute myeloid leukemia (AML) has returned after treatment. The drug may help block cancer cell growth. The study also looks at safety and how well the drug works when given alone or with other treatments.
Washington D.C., District of ColumbiaAges 4 weeks–21 years - NCT05621291Recruiting
Sequencing test to guide care after CD19 CAR T in kids
This study checks a DNA-based lab test (next-generation sequencing, or NGS) to monitor B-cell recovery after CD19 CAR T treatment in children and young adults. The goal is to see whether the test can help guide management while looking for remission and safe recovery.
Washington D.C., District of ColumbiaAges 1–25 - NCT03739814RecruitingPhase 2
Test inotuzumab, blinatumomab, and possibly ponatinib for CD22 ALL
This Phase 2 study tests a combination of medicines (inotuzumab ozogamicin and blinatumomab), with or without ponatinib, for people with CD22-positive B-cell acute lymphoblastic leukemia (ALL). It aims to improve remission and control leukemia cells, including in the bone marrow.
Washington D.C., District of ColumbiaAges 18 years+ - NCT01351545Recruiting
Cryopreserved cord blood access program for transplant patients
This trial studies an organized way to obtain and distribute unlicensed (not FDA-approved for general use) stored cord blood units that have been frozen and kept. It may help people who need a cord blood transplant but don’t fit the “licensed cord blood only” options.
Washington D.C., District of ColumbiaAges Any age - NCT04988555RecruitingPhase 1/Phase 2
Study of an investigational drug for high-risk acute leukemia
This Phase 1/2 study tests enzomenib (DSP-5336) in people with relapsed or hard-to-treat acute leukemia (and, in some places, certain other blood cancers). The goal is to see how the drug works and how safe it is, especially for leukemia cases with specific genetic changes (KMT2A/MLL or NPM1).
Washington D.C., District of ColumbiaAges 12 years+ - NCT04990102RecruitingPhase 1/Phase 2
Trial drug to help prevent relapse in AML
This trial tests CPX-351 to help stop acute myeloid leukemia (AML) from coming back after you’ve reached remission. It’s for people who are not able to receive a stem cell transplant and need a new way to reduce relapse risk.
Washington D.C., District of ColumbiaAges 18 years+ - NCT04269902RecruitingPhase 3
Early treatment check for high-risk CLL/SLL
This Phase 3 trial studies an early treatment approach for people with high-risk CLL or SLL who have not yet needed standard therapy. It aims to see if treating earlier can improve outcomes while keeping side effects manageable.
Washington D.C., District of ColumbiaAges 18 years+ - NCT06124157RecruitingPhase 2
Targeted therapy plus chemo for children with Ph+ or Ph-like B-ALL
This trial tests if adding a targeted drug (dasatinib or imatinib) to a chemotherapy combination with blinatumomab works better for children and young adults with a specific genetic form of B-cell acute lymphoblastic leukemia. The goal is to see if this approach can improve treatment outcomes for patients with Philadelphia chromosome-positive or ABL-class Ph-like B-ALL.
Washington D.C., District of ColumbiaAges 1 year–46 years - NCT04972942RecruitingPhase 1
Immunotherapy for high-risk T-cell blood cancers after transplant
This Phase 1 study tests a targeted immune treatment given after strong pre-treatment (myeloablative chemo plus total-body radiation) before or along with an allogeneic stem cell transplant. It may help prevent the cancer from coming back in young people with high-risk T-cell ALL or certain T-cell lymphomas.
Washington D.C., District of ColumbiaAges Up to 39 years - NCT06960993Recruiting
Mosaic trial for stem cell transplant patients
This trial tests a website designed to help patients learn about stem cell transplants for blood cancers. It aims to support you during your transplant journey.
Washington D.C., District of ColumbiaAges 18 years+ - NCT03633955RecruitingPhase 1
Imaging study for people with high-risk leukemia
This early (Phase 1) study tests how a special scan works in people with relapsed or hard-to-treat leukemia types. The scan uses a tracer called 18F FLT, and the study looks to see if it can be done safely (without sedation) and how it relates to treatment.
Washington D.C., District of ColumbiaAges 4–80 - NCT03959085RecruitingPhase 3
Inotuzumab plus chemotherapy for high-risk childhood leukemia
This Phase 3 trial tests whether adding inotuzumab to standard post-induction chemotherapy improves outcomes for children and young teens with high-risk B-ALL, mixed phenotype acute leukemia (MPAL), or certain high-risk B-LLy. It may help by targeting leukemia cells more directly, but participation depends on specific age, lab results, and medical history rules.
Washington D.C., District of ColumbiaAges 12 months–25 years - NCT05334069Recruiting
Blood test study for early cancer detection in patients
This study collects blood from people with cancer and people without cancer (or with possible cancer) to test whether new blood tests can detect cancer earlier. Your blood samples help researchers evaluate how well these tests work.
Washington D.C., District of ColumbiaAges 40–75 - NCT06973187RecruitingPhase 3
Comparing two drugs for CLL or SLL after prior treatment
This trial tests a new drug (BGB-16673) against another drug (pirtobrutinib) for people with CLL or SLL that hasn't responded to or has come back after a prior BTK inhibitor treatment. The goal is to see which drug is more effective and safe.
Washington D.C., District of ColumbiaAges 18 years+ - NCT06247787RecruitingPhase 1
Imetelstat plus chemo for relapsed leukemia in kids
This trial tests a new drug called imetelstat combined with two chemotherapy drugs (fludarabine and cytarabine) for children and teens with acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), or juvenile myelomonocytic leukemia (JMML) that has come back or not responded to treatment. The goal is to find the safest dose of imetelstat and see if it helps control the cancer.
Washington D.C., District of ColumbiaAges 1–18 - NCT02203903RecruitingPhase 1
Donor T-cell treatment after transplant for high-risk AML and MDS
This Phase 1 trial studies an advanced form of donated immune cells given after a stem cell transplant to help prevent leukemia coming back. It mainly looks at safety and whether the treatment can work in people with very high-risk AML or MDS who have not relapsed.
Washington D.C., District of ColumbiaAges 6 months–80 years - NCT04293562RecruitingPhase 3
Comparing chemotherapy options for newly diagnosed AML in young patients
This trial compares standard chemotherapy with newer drug combinations (CPX-351 and gilteritinib) for children and young adults with acute myeloid leukemia (AML), a type of blood cancer. It aims to find which treatment works better and who might benefit from targeted therapy based on specific genetic changes (FLT3 mutations).
Washington D.C., District of ColumbiaAges 6 months–21 years - NCT06892158Recruiting
Massage therapy for sleep in teens with cancer
This trial studies if massage therapy can help teenagers and young adults with cancer sleep better while they are in the hospital. Participants will receive massage sessions and answer questions about their sleep.
Washington D.C., District of ColumbiaAges 12–21 - NCT04726241RecruitingPhase 1/Phase 2
Testing blood and bone marrow samples in young leukemia patients
This trial looks at blood and bone marrow samples from children and teens whose leukemia has come back or is hard to treat. The goal is to better understand the disease and guide future options for these patients.
Washington D.C., District of ColumbiaAges Up to 22 years - NCT06317662RecruitingPhase 2
Adding venetoclax and blinatumomab to chemo for infant leukemia
This trial tests adding two newer medicines (venetoclax and blinatumomab) to standard chemotherapy for infants with a specific type of leukemia. The goal is to see if this combination helps more babies stay cancer-free.
Washington D.C., District of ColumbiaAges Up to 12 months - NCT05955261RecruitingPhase 2
Study of adding venetoclax to standard chemotherapy for pediatric AML
This trial tests a new combination of a targeted pill (venetoclax) with standard chemotherapy for children and young adults with acute myeloid leukemia (AML). The hope is that adding venetoclax will improve how well the chemo works and reduce the chance of the leukemia coming back.
Washington D.C., District of ColumbiaAges 4 weeks–21 years - NCT05849662RecruitingPhase 1/Phase 2
Trametinib plus azacitidine for newly diagnosed JMML
This trial studies whether trametinib and azacitidine can control juvenile myelomonocytic leukemia (JMML) soon after diagnosis. It’s designed to test safety and how well the treatment works in children and young adults who meet specific leukemia and genetic criteria.
Washington D.C., District of ColumbiaAges 1 month–21 years - NCT06722638Recruiting
Virtual reality for lumbar punctures in leukemia
This study tests if using a virtual reality headset during a lumbar puncture (a spinal tap) can help children feel less pain and anxiety. It is for children with acute lymphoblastic leukemia (ALL) or lymphoma who are in the maintenance phase of treatment.
Washington D.C., District of ColumbiaAges 7 years+ - NCT04546399RecruitingPhase 2
Blinatumomab with or without nivolumab for first relapse ALL
This study compares blinatumomab alone versus blinatumomab plus nivolumab in young people whose B-cell ALL has returned for the first time. It aims to see whether adding nivolumab improves control of the leukemia after relapse.
Washington D.C., District of ColumbiaAges 1–30
Hear when a new Leukemia trial opens near Washington, D.C., DC
We’ll email you when one opens near Washington, D.C., DC — at most once a week, no account needed, unsubscribe anytime.
Leukemia trials in other cities
Where these studies are running near Washington, D.C.
Institutions with a site for the recruiting leukemia studies listed above.
- Children's National Medical Center · 12 studies
- Johns Hopkins University · 8 studies
- MedStar Georgetown University Hospital · 8 studies
- Sinai Hospital of Baltimore · 7 studies
- Walter Reed National Military Medical Center · 7 studies
- Inova Fairfax Hospital · 5 studies
- University of Maryland/Greenebaum Cancer Center · 3 studies
- Children's National Hospital · 2 studies
What taking part in a leukemia study involves
A screening visit first
Before anything else, the study team checks whether you fit — usually a visit with some tests. You can stop at any point, and screening is typically free.
Care at a nearby site
Study visits happen at a clinic or hospital taking part. Many studies cover the cost of the study treatment and related visits, and some reimburse travel.
You stay in control
Taking part is voluntary and you can leave a study at any time, for any reason, without affecting your regular care.
The team decides eligibility
Our fit check is a helpful first read, not a decision. The study team makes the final call after reviewing your health history.
Common questions
- Are there leukemia clinical trials near Washington, D.C.?
- Yes. We're currently tracking 106 recruiting leukemia studies with a site near Washington, D.C., each rewritten in plain language so you can see what it's testing and who it's for.
- How do I find out if I qualify for a leukemia study near Washington, D.C.?
- Each study lists its eligibility rules — age, diagnosis, prior treatments. On every trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Do I have to live in Washington, D.C. to take part?
- Not necessarily. These studies have a site near Washington, D.C., but eligibility is about your health, not your address — some people travel to take part, and a few studies reimburse travel. The study team can tell you what's required.
- Does it cost anything to join a leukemia trial?
- Using Clin2 is always free. Many trials cover the study treatment and related visits; some reimburse travel. The study team explains exactly what's covered before you decide.
Not the right time?
New leukemia studies open near Washington, D.C. regularly. Set up a health profile and we’ll quietly watch for studies that fit you and email you when one opens.